Key result
Polyvascular disease in new-onset AF is linked to ~43% higher all-cause mortality.
Why the study?
AF frequently coexists with atherosclerotic disease, but the impact of polyvascular involvement on clinical outcomes and risk stratification remained unclear.
Does the presence of polyvascular disease increase the risk of mortality and cardiovascular events and improve stroke risk discrimination when added to the CHA2DS2VA score in patients with newly diagnosed atrial fibrillation?
Cohort (n=198,995)
Yes
Does the presence of polyvascular disease increase the risk of mortality and cardiovascular events and improve stroke risk discrimination when added to the CHA2DS2VA score in patients with newly diagnosed atrial fibrillation?
In patients with newly diagnosed atrial fibrillation, polyvascular disease is strongly associated with worse survival and increased cardiovascular events, though adding it to the CHA2DS2VA score does not improve stroke risk discrimination.
Answers are grounded in this paper and cite their sources.
Polyvascular disease was associated with higher mortality in new AF; leaves open whether it enhances CHA2DS2VA for stroke risk stratification.
Background Atrial fibrillation (AF) frequently coexists with atherosclerotic disease, but the impact of polyvascular involvement on clinical outcomes and risk stratification remains unclear. Methods Using linked UK electronic health records, we identified patients with newly diagnosed AF between 1998 and 2016. Patients were classified according to vascular disease extent (none, single-arterial, or polyvascular). Associations with mortality and cardiovascular events were assessed using Cox regression. We evaluated whether adding one point for polyvascular disease to the CHA2DS2VA score improved discrimination for stroke and systemic embolism. Results Among 198,995 patients, 10.3% had polyvascular disease and 33.9% had single-arterial involvement. Over a median follow-up of 5.9 years, increasing vascular burden was associated with greater comorbidity and higher rates of cardiovascular events. All-cause mortality increased progressively across patients with no vascular disease (42.7%), single-arterial disease (53.2%), and polyvascular disease (62.3%; log-rank P<0.001). Following multivariable adjustment, both single-arterial (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.16–1.19) and polyvascular disease (HR 1.43, 95% CI 1.40–1.46) independently predicted mortality. Polyvascular disease was also associated with increased risks of heart failure hospitalization, myocardial infarction, and ischemic stroke. Adding polyvascular disease to the CHA2DS2VA risk scheme did not result in an appreciable change in discriminative performance for ischemic stroke (c-index 0.67, 95%CI 0.66-0.67 for both CHA2DS2VA and CHA2DS2VA+polyvascular). Conclusions Vascular disease is common in newly diagnosed AF and is associated with progressively worse cardiovascular outcomes and survival. Incorporating polyvascular disease in the CHA2DS2VA score did not enhance its discriminative capacity.
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2026) conducted a cohort in Newly diagnosed atrial fibrillation (n=198,995). Polyvascular disease vs. No vascular disease was evaluated on All-cause mortality (HR 1.43, 95% CI 1.40-1.46, p=<0.001). Polyvascular disease in newly diagnosed atrial fibrillation independently increased all-cause mortality vs no vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: